Private equity-backed US-based contact lens maker Bausch & Lomb is reportedly looking to raise $100m via an IPO.
J.P.Morgan, BofA Merrill Lynch and Citigroup will be the lead underwriters for the company, which is backed by Warburg Pincus, said Reuters, citing a filing with the US Securities and Exchange Commission.
The filing did not show how many shares would be offered as part of the IPO or their indicative price range.
The agency has previously reported that the proposed float could raise up to $1.5bn and value the business at between $9bn and $10bn.
It also said Warburg – which acquired the company in a $4.5bn take-private that included debt financing of $830m in 2007 – is still considering a private sale of the company and has hired Goldman Sachs to find a suitor.
Potential bidders for Bausch & Lomb include GlaxoSmithKline, Pfizer, Bayer, Merck, Sanofi and Abbot Group, the FT has said.
Back in December it was reported that Warburg was eyeing a $10bn sale of Bausch & Lomb.
Since inception, Warburg Pincus has invested over $8.1bn in more than 140 healthcare companies.
In addition to Bausch, some of its investees included American Medical Systems, Bausch + Lomb, Coventry Health Care, Eurand, Euromedic International, Harbin Pharmaceuticals, Lepu Medical Technology, RegionalCare Hospital Partners, Rural/Metro Corporation, Tornier and Zentiva.
Copyright © 2013 AltAssets